

## Monday 28 January 2019

### Side meetings 9:00-16:30

Time		
9:00-16:30	INTEGRATE Partnership Forum Meeting. Room: Enescu 1	All INTEGRATE partners + AB members
15:30-16:30	Press Conference. Room: Regina Maria 2	Conference Chairs: Jürgen Rockstroh, Daniel Simões, Adrian Streinu-Cercel
12:30-19:30	<b>Registration open</b>	
Time	Room: Le Diplomate	Moderators and speakers
17:00-19:00	<b>OPENING SESSION</b>	<b>Moderators:</b> Jürgen Rockstroh, Daniel Simões, Adrian Streinu-Cercel
	<b>Objectives:</b> <ul style="list-style-type: none"> <li>Provide an overview of the need for and work towards integration of testing of infectious diseases in Europe</li> <li>Introduce the policy framework in Romania and Europe</li> </ul>	
17:00-17:15	Welcome: conference objectives and overview	Conference Chairs: Jürgen Rockstroh, Daniel Simões, Adrian Streinu-Cercel
17:15-17:30	Recent trends and testing initiatives in Romania	Minister of Health Romania, Hon. Sorina Pintea (TBC)
17:30-17:45	European Commission policy of integration of infectious diseases	Vytenis Andriukaitis, European Commissioner for Health and Food Safety (by video)
17:45-18:00	HIV and HCV trends in the EU	Andrew J. Amato Gauci, ECDC
18:00-18:15	WHO welcome remarks: the targets in the European Region	Masoud Dara on behalf of Regional Director Zuzsanna Jakab, WHO Regional Office for Europe
18:15-18:30	European Community Perspective on stigma as a continued barrier to testing for Hep/HIV	Sini Pasanen, Civil Society Forum
18:30-18:45	The HIV in Europe initiative – past, present and future	Brian Gazzard, Chelsea and Westminster Hospital
19:00	<b>Reception – at venue</b>	

## Tuesday 29 January 2019

Time	Room: Le Diplomate	Moderators and speakers
8:30	Registration: Registration counter in lobby	
8:45-10:15	<b>PLENARY SESSION 1: Epidemiological and testing policy overview: where are we in reaching the targets?</b>  <b>Objectives:</b> <ul style="list-style-type: none"> <li>To provide an overview of epidemiological trends and testing policies in light of integration of testing for Hepatitis and HIV</li> </ul>	<b>Moderators: Cristiana Oprea and Nikos Dedes</b>
8:45-9:00	Monitoring the response to Hepatitis and HIV in Europe and Central Asia: Are we on track to reach agreed targets?	Teymur Noori, ECDC
9:00-9:15	HIV and viral hepatitis response under UHC approach – WHO Guidance on testing strategies and linkage to care	Elena Vovc, WHO Regional Office for Europe
9:15-9:30	PWID and prisoners: Priority populations for testing	Jane Mounteney, Head of Public Health Unit, EMCDDA
9:30-9:45	Affordability and cost-effectiveness of hepatitis and HIV testing	Yazdan Yazdanpanah, INSERM
9:45-10:15	Discussion	
10:15-10:45	<b>Coffee break: Les Collonades</b>	
Time	Room: Le Diplomate	Moderators and speakers
10:45-12:30	<b>PLENARY SESSION 2: Combination prevention</b>  <b>Objectives:</b> <ul style="list-style-type: none"> <li>To discuss implementation progress and challenges in the use of combination prevention interventions</li> <li>To present new testing modalities and linkage to care</li> </ul>	<b>Moderators: Brian West and Deniz Gökengin</b>
10:45-11:00	PrEP – effective community mobilization	Will Nutland, PrEPster
11:00-11:15	Harm reduction, testing and linkage to care	Jason Farrell, Correlation Network
11:15-11:30	U=U – how to deal with prevention	Valentina Cambiano, PARTNER, UCL
11:30-11:45	Self-testing – what is the status in Europe and how do we monitor linkage to care?	Viatcheslav Grankov, WHO Country Office in Belarus Sniazhana Biadrytskaya, National Center for Hygiene, Epidemiology and Public Health
11:45-12:00	Partner notification: high potential but limited implementation	Tom Platteau, HIV/STI clinic of the Institute of Tropical Medicine in Antwerp
12:00-12:30	Discussion	
12:30-13:30	<b>Lunch: Les Collonades</b>	<b>Testing Week Meeting: Regina Maria 2 (bring your lunch to the meeting)</b>

Time	Room: Le Diplomate	Room: Regina Maria 2
13:30-14:45	<b>PARALLEL SESSION 1: Monitoring and Evaluation</b> <b>Moderators: Dagmar Hedrich and Jordi Casabona</b>	<b>PARALLEL SESSION 2: Combination Prevention</b> <b>Moderators: John S. Lambert and Lella Cosmaro</b>
13:30-13:45	<b>PS1/01 High contribution, low public funding: Southern European Checkpoints' role in HIV detection in 4 countries</b> <u>M. Rocha</u> <sup>1</sup> , F. Pujol Roca <sup>2</sup> , J. Saz Berges <sup>2</sup> , S. Chanos <sup>3</sup> , G. Polkas <sup>4</sup> , S. Mattioli <sup>5</sup> , D. Garcia <sup>6</sup> , A. Bertó Moran <sup>6</sup> , P. Meireles <sup>7</sup> , D. Simões <sup>8</sup>	<b>PS2/01 On Social Media Mining for HIV Pre-Exposure Prophylaxis</b> <u>C. Kakalou</u> <sup>1</sup> , J.V. Lazarus <sup>2</sup> , V. Koutkias
13:45-14:00	<b>PS1/02 HIV dynamics in the most affected area of Europe: a tale of two countries</b> <u>L. Marty</u> <sup>1</sup> , L. Lemsalu <sup>2</sup> , D. Costagliola <sup>1</sup> , K. Vals <sup>2</sup> , R. Kaupé <sup>3,4</sup> , I. Linina <sup>3</sup> , I. Upmace <sup>3,5</sup> , A. Kivite <sup>3</sup> , V. Supervie <sup>1</sup> , HERMETIC study group	<b>PS2/02 HIV infection and associated risk factors among Female (Cis &amp; Trans) and Male Sex Workers in Greece: Innovative evidence by "Red Umbrella Athens"</b> <u>M. Xanthaki</u> <sup>1</sup> , A. Poulis <sup>2</sup> , S. Chanos <sup>3</sup> , G. Gkogidis <sup>4</sup> , A. Kouroupou <sup>1</sup> , S. Matis <sup>3</sup> , D. Antoniou <sup>1</sup> , A. Papatrechas <sup>1</sup> , P. Triantafillou <sup>1</sup> , A. Christopoulos <sup>5</sup>
14:00-14:15	<b>PS1/03 "Routine testing" as primary reason for getting tested for HIV in MSM: results from the first participants enrolled in the COBA-Cohorts project</b> <u>N. Lorente</u> <sup>1,2</sup> , P. Meireles <sup>3</sup> , M. Rocha <sup>4</sup> , L. Kehlet <sup>5</sup> , M. Cosic <sup>6</sup> , S. Chanos <sup>7</sup> , G. Polkas <sup>7</sup> , S. Morel <sup>8</sup> , D. Rojas Castro <sup>8,9,10</sup> , L. Cosmaro <sup>11</sup> , C. Agustí <sup>1,2,12</sup> , L. Fernández-López <sup>1,2,12</sup> , J. Casabona <sup>1,2,12</sup> , COBA-Cohorts Study group	<b>PS2/03 A nationwide combination prevention success in England: intensified testing and earlier treatment controls HIV transmission in men-who-have-sex-with-men as well as benefiting others</b> <u>N. Gill</u> <sup>1</sup> , F. Brizzi <sup>2</sup> , P.J. Birrell <sup>2,3</sup> , P. Kirwan <sup>1</sup> , D. Ogaz <sup>1</sup> , A.E. Brown <sup>1</sup> , V.C. Delpech <sup>1</sup> , D. De Angelis <sup>2</sup>
14:15-14:30	<b>PS1/04 National multi-stakeholder produced standards for HIV partner notification improve outcomes</b> <u>A. Sullivan</u> <sup>1</sup> , L. Bull <sup>1</sup> , H. Curtis <sup>2</sup> , V. Apea <sup>3</sup> , M. Rayment <sup>1</sup> , BASHH National Audit Group	<b>PS2/04 Programmatic Mapping and Size Estimation of Key Populations in two major cities in Turkey: Istanbul and Ankara</b> G. Aybek <sup>1</sup> , F. Emmanuel <sup>2</sup> , <u>D. Gokengin</u> <sup>3,4</sup> , J.F. Blanchard <sup>2</sup> , D. Serter <sup>1</sup> , S.O. Aral <sup>5</sup>
14:30-14:45	<b>PS1/05 Independent of injecting drug use, being a foreign national is associated with risk of reactive HCV screening in European community-based testing services in 2017</b> <u>A. Conway</u> <sup>1,2</sup> , N. Lorente <sup>1,2</sup> , L. Fernández López <sup>1,2,3</sup> , J. Casabona <sup>1,2,3</sup> , COBATEST Network Study Group	<b>PS2/05 Contribution of anonymous partner notification service on HIV/sexual transmitted infection (STI) detection at a community-based sexual health centre for men who have sex with men (MSM)</b> <u>M. Rocha</u> <sup>1,2</sup> , P. Meireles <sup>3</sup> , D. Simões <sup>1,2</sup> , H. Barros <sup>3,4</sup>
14:45-15:00	<b>Short break</b>	

Time	Room: Le Diplomate	Moderators and speakers
15:00-16:15	<b>Round Table Discussion: Fast track cities initiatives: How to expand to other disease areas</b>  <b>Objectives:</b> <ul style="list-style-type: none"> <li>To discuss how to translate global and regional goals, objectives and targets into local implementation plans</li> <li>To present concrete examples of fast track city initiatives that integrate disease areas</li> </ul>	<b>Moderators: Valerie Delpech (TBC) and John de Wit</b>
15:00-15:15	Key population and stigma – can global/regional initiatives push the agenda?	Yusef Azad, National AIDS Trust
15:15-15:30	<i>Short interventions on local experiences:</i> Successful models for 90-90-90 for HIV and TB, community involvement and municipal leadership	Tatyana Deshko, Ukrainian Alliance for Public Health Maia Tsereteli, HIV/AIDS, Hepatitis, STI & TB Division at the National Center for Disease Control and Public Health Georgia
15:30-16:15	Panel discussion: Fast track cities in EE: the role of FTC in the response to other epidemics	<b>Panel members:</b> Yusef Azad, National AIDS Trust Tatyana Deshko, Ukrainian Alliance for Public Health Maia Tsereteli, HIV/AIDS, Hepatitis, STI & TB Division at the National Center for Disease Control and Public Health Georgia Udi Davidovich, Amsterdam Public Health Service, University of Amsterdam Wolfgang Philipp, DG Sante Luxembourg Bertrand Audoin, IAPAC Sophocles Chanos, Athens Checkpoint - Positive Voice
16:15-17:00	<b>Coffee break and Posters: Les Collonnades + Regina Maria 1</b>	
Time	Room: Le Diplomate	
17:00-18:30	<b>EU Health Project Symposium: Integrated Testing and Synergies</b> <b>Moderators: Wolfgang Philipp and Jens Lundgren</b> <b>Objectives:</b> <ul style="list-style-type: none"> <li>To share experiences on successful testing interventions and discuss how integration of testing can be improved and implemented</li> <li>To highlight synergies between ongoing European projects and discuss sustainability and transferability</li> </ul>	
17:00-17:15	Service integration – Reaching the homeless population	John S. Lambert, HepCARE
17:15-17:30	Options for integrated TB, HIV and hepatitis service delivery in Romania	Gerard de Vries, E-detect TB

17:30-17:45	Integrated testing (TBC)	(TBD), INTEGRATE
17:45-18:00	Integrated testing and services to people who use drugs	Alexandra Gurinova, HA-React
18:00-18:15	Staff training: A way to strengthen integrated prevention and health care for MSM	Matthias Kuske Deutche AIDS Hilfe & Barrie Dwyer THT, Esticom
18:15-18:30	Discussion	
18:30-19:30	<b>Co-Chairs and rapporteurs: HepHIV2019 office</b>	
20:00	<b>Conference Dinner: Restaurant Caru' cu bere</b>	

<b>Wednesday, 30 January 2019</b>		
<b>Time</b>	<b>Room: Le Diplomate</b>	<b>Moderators and speakers</b>
7:00-8:00	<b>HIV in Europe SC and HepHIV 2019 OC Meeting: Enescu 2</b>	
8:30-10:00	<b>Special session: The elimination of HIV and hepatitis agenda: what needs to be done?</b>  <b>Objectives:</b> <ul style="list-style-type: none"> <li>To give an overview of the international agenda and discuss current status in reaching the targets</li> <li>To discuss strategies to ensure earlier diagnosis of hepatitis among priority populations</li> </ul>	<b>Moderators: Jeff Lazarus and Liudmyla Maistat</b>
8:30-8:40	Short report from Conference Day 1	Conference chairs
8:40-8:55	Possibilities with new testing algorithms and technologies	Anita Sands, WHO Geneva (TBC)
8:55-9:10	Micro-elimination of hepatitis in prisons	Fadi Meroueh, USMAV
9:10-9:25	Testing as part of elimination strategies – finding the missing millions	EASL rep.(TBD)
9:25-10:00	Panel Discussion: How does the integration agenda support the elimination agenda?	Panel members: Anita Sands, WHO Geneva (TBC) Fadi Meroueh, USMAV EASL rep.(TBD) Dagmar Hedrich, EMCDDA Raquel Peck, World Hepatitis Alliance Ganna Dovbakh, EHRA Sergey Golovin, ITPC Antons Mozalevskis, WHO Regional Office for Europe Tatjana Reic, ELPA Stanslas Pol, Université Paris Descartes (TBC)
10:00-10:30	<b>Coffee break/Posters: Les Collonnades + Regina Maria 1</b>	

Time	Room: Le Diplomate	Room: Regina Maria 2
10:30-11:45	<b>PARALLEL SESSION 3: Integrated Testing Strategies</b> <b>Moderators: Sini Pasanen and Masoud Dara</b>	<b>PARALLEL SESSION 4: Linkage to Care</b> <b>Moderators: Yusef Azad and (TBD)</b>
10:30-10:45	<b>PS3/01 The ENABLE study; High prevalence of undiagnosed blood borne virus infections (HBV, HCV, HIV) in urban emergency department attenders in England- a case for opportunistic testing?</b> <u>Z. Mohamed</u> <sup>1</sup> , M. Hopkins <sup>2</sup> , A. Brown <sup>1</sup> , D. Muir <sup>3</sup> , S. Todd <sup>4</sup> , M. Beadsworth <sup>4</sup> , R. Vivancos <sup>5</sup> , C. Anderson <sup>5</sup> , A. Guleri <sup>6</sup> , R. Sharma <sup>6</sup> , R. Palmer <sup>6</sup> , D. Singleton <sup>6</sup> , M. Ruf <sup>7</sup> , A. Chawla <sup>4</sup> , The ENABLE group	<b>PS4/01 Hepcheck- Enhancing HCV identification and linkage to care for vulnerable populations through intensified outreach screening</b> S. Barror <sup>1</sup> , G. Avramovic <sup>2</sup> , M. Iglesias <sup>3</sup> , I. Ianache <sup>4</sup> , A.M. Naughton <sup>5</sup> , C. Oprea <sup>4</sup> , J. Surey <sup>6</sup> , A. Story <sup>7</sup> , J. Macías <sup>3</sup> , W. Cullen <sup>2</sup> , W. Tinago <sup>2</sup> , <u>J. Lambert</u> <sup>1,2</sup>
10:45-11:00	<b>PS3/02 SH:24 - An online sexual health service using digital technology to increase access to HIV testing in London</b> R. Coyle <sup>1</sup> , S. Amos-Gibbs <sup>1</sup> , E. Ardines <sup>1</sup> , C. Howroyd <sup>1</sup> , <u>G. Holdsworth</u> <sup>1</sup>	<b>PS4/02 HepLink: Findings from a Multi-centre Observational Study in Primary and Community Care</b> E. Nic An Riogh <sup>1</sup> , D. Swan <sup>1</sup> , G. McCombe <sup>1</sup> , E. O'Connor <sup>1,2</sup> , G. Avramovic <sup>1</sup> , J. Macías <sup>3</sup> , C. Oprea <sup>4,5</sup> , A. Story <sup>6</sup> , J. Surey <sup>7</sup> , P. Vickerman <sup>8</sup> , Z. Ward <sup>8</sup> , <u>J. Lambert</u> <sup>1,2</sup> , W. Tinago <sup>1</sup> , I. Ianache <sup>4</sup> , M. Iglesias <sup>3</sup> , W. Cullen <sup>1</sup>
11:00-11:15	<b>PS3/03 Tuberculosis in the time of HIV: what impede the injecting drug users (IDUs) from Romania to address diagnosis and treatment services for TB? Results from a mixed methods study</b> <u>L. Verdes</u> <sup>1,2</sup> , M. Dan <sup>1,2</sup> , R. Delabre <sup>2</sup> , D. Rojas-Castro <sup>2</sup> , F. Kalambayi <sup>3</sup> , A. Toth <sup>3</sup>	<b>PS4/03 Processes of data collection on HIV, viral hepatitis and STI testing and linkage to care at national level in European countries: a review for the Integrate Joint Action</b> <u>A. Conway</u> <sup>1,2</sup> , L. Fernández López <sup>1,2,3</sup> , N. Lorente <sup>1,2</sup> , I. Klavs <sup>4</sup> , M. Serdt <sup>4</sup> , Y. Azad <sup>5</sup> , R. Hayes <sup>5</sup> , V. Delpech <sup>6</sup> , A. Brown <sup>6</sup> , J. Casabona <sup>1,2,3</sup> , INTEGRATE Steering Committee
11:15-11:30	<b>PS3/04 Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: a systematic review</b> L. Mason <sup>1</sup> , I. Veldhuijzen <sup>2</sup> , E. Duffell <sup>3</sup> , A. van Ahee <sup>1</sup> , A. Amato Gauci <sup>3</sup> , <u>L. Tivoschi</u> <sup>3,4</sup>	<b>PS4/04 Community-based HIV testing in Europe: a systematic review</b> <u>S. Croxford</u> <sup>1</sup> , L. Tivoschi <sup>2,3</sup> , A. Sullivan <sup>4</sup> , L. Combs <sup>5</sup> , D. Raben <sup>5</sup> , V. Delpech <sup>1</sup> , S. Finne Jakobson <sup>5</sup> , A. Amato-Gauci <sup>2</sup> , S. Desai <sup>1</sup>
11:30-11:45	<b>PS3/05 Evidence-based public health guidance for integrated HBV, HCV and HIV testing in Europe</b> <u>A.K. Sullivan</u> <sup>1</sup> , S. Croxford <sup>2</sup> , S. Desai <sup>2</sup> , L. Combs <sup>3</sup> , L. Tivoschi <sup>4,5</sup> , L. Mason <sup>6</sup> , V. Delpech <sup>2</sup> , M. Hoekstra <sup>7</sup> , S.F. Jakobsen <sup>3</sup> , A.J. Amato-Gauci <sup>4</sup> , D. Raben <sup>3</sup>	<b>PS4/05 Can We Report the Status of a Cascade of Care for Viral Hepatitis B and C in Romania? The Experience of Baylor Foundation's Hepatitis Screening and Care Program in Dobrogea Region between 2010 - 2018</b> <u>A.-M. Schweitzer</u> <sup>1</sup> , M. Bogdan <sup>1</sup> , A. Corduneanu <sup>1</sup> , I. Ciocea <sup>1</sup>
11:45-12:45	<b>Lunch: Les Collonades</b> <b>Cochairs + rapporteurs: HepHIV2019 Office</b>	

Time	Room: Le Diplomate	Moderators and speakers
<b>12:45-14:15</b>	<b>PLENARY SESSION 3: Linkage to care and treatment for better outcomes: good models and challenges</b> <b>Objectives:</b> <ul style="list-style-type: none"> <li>To share successful linkage to care and integration of services practices</li> <li>To discuss the role of civil society in ensuring linkage to care</li> </ul>	<b>Moderators: Nino Tsereteli and Andrew Amato</b>
12:45-13:00	Defining linkage to care and challenges in monitoring	Valerie Delpech, Public Health England
13:00-13:15	Linkage to treatment – involving primary care	Margaret Hellard, Burnet Institute
13:15-13:30	Community Based Testing as part of the National formal strategies for early diagnosis and treatment of HIV/STI and Viral Hepatitis	Jordi Casabona, CEEISCAT
13:30-13:45	The role of civil society in the integration of services and linkage to care in key populations	Eberhard Schatz, Correlation Network
13:45-14:15	Discussion	
<b>14:15-14:30</b>	<b>Coffee break: Les Collonnades</b>	
Time	Room: Le Diplomate	Moderators and speakers
<b>14:30-16:15</b>	<b>CLOSING SESSION: Integration of services</b> <b>Objectives:</b> <ul style="list-style-type: none"> <li>To sum up and highlight upcoming focus areas for integration of service delivery in infectious diseases</li> <li>To present and discuss the conference call to action and implication for policy and implementation agendas</li> </ul>	<b>Moderators: Ann Sullivan and Jürgen Rockstroh</b>
14:30-14:40	Short report from Conference Day 2	Conference chairs
14:40-15:00	Integration of services in the personalized medicine agenda: integrating disease areas and settings	Jens Lundgren, CHIP, Rigshospitalet
15:00-15:20	Quality of Life and Participation and integration of patient voices in decision making and the response to HIV and Viral Hepatitis	Ricardo Baptista Leite, Member of Parliament
15:20-15:40	Quality of life indicators	Richard Harding, Kings' College London
15:40-16:00	Challenges ahead in Eastern Europe and Central Asia	Michel Kazatchkine, UN Secretary-General's Special Envoy on HIV/AIDS in Eastern Europe and Central Asia
16:00-16:15	Conference call to action	Conference chairs

## **Poster Sessions: Tuesday 29 January from 16:15-17:00 and Wednesday 30 January from 10:00-10:30**

### **Poster Category 1: Monitoring and Evaluation**

#### **PO1/01 Impact of Adam's Love Online-to-Offline (O2O) model in monitoring and evaluation of HIV prevention cascade among men who have sex with men (MSM)**

T. Anand<sup>1</sup>, C. Nitpolprasert<sup>1</sup>

<sup>1</sup>Adam's Love Global Foundation for MSM and Transgender Health (ALGO), Bangkok, Thailand

#### **PO1/02 Screening for hepatitis B virus and accelerated vaccination schedule in prison: A pilot multicenter study**

C. Stasi<sup>1</sup>, M. Monnini<sup>1</sup>, V. Cellesi<sup>2</sup>, M. Salvadori<sup>3</sup>, D. Marri<sup>4</sup>, M. Ameglio<sup>5</sup>, A. Gabbuti<sup>6</sup>, T. Di Fiandra<sup>7</sup>, F. Voller<sup>1</sup>, C. Silvestri<sup>1</sup>

<sup>1</sup>Regional Health Agency of Tuscany, Florence, Italy, <sup>2</sup>Local Healthcare Tuscany North West, Volterra, Italy, <sup>3</sup>Local Healthcare Tuscany Centre, Florence, Italy, <sup>4</sup>Infectious Diseases and Hepatology Unit, University Hospital of Siena, Siena, Italy, <sup>5</sup>Departmental Operational Units in prison, Local Healthcare Tuscany Southeast, Colle Val D'Elsa, Siena, Italy, <sup>6</sup>Local Healthcare Tuscany Centre, Florence, Italy, <sup>7</sup>General Directorate for Health Prevention, Ministry of Health, Rome, Italy

#### **PO1/03 Missed opportunities for HIV testing of patients diagnosed with an indicator condition in primary care in Catalonia, Spain**

C. Agustí<sup>1</sup>, A. Montoliu<sup>1</sup>, M. Juanjo<sup>2</sup>, R. Carrillo<sup>3</sup>, J. Almeda<sup>4</sup>, J. Casabona<sup>1</sup>

<sup>1</sup>CEEISCAT-Agència de Salut Pública de Catalunya, Badalona, Spain, <sup>2</sup>Sociedad Española de Medicina Familiar y Comunitaria (semFYC), Barcelona, Spain, <sup>3</sup>Societat Catalana de Medicina Familiar i Comunitària (CAMFiC), Barcelona, Spain, <sup>4</sup>Institut Català de la Salut (ICS), Unitat de Suport a la Recerca. Direcció d'Atenció Primària Costa de Ponent, Cornellà de Llobregat, Spain

#### **PO1/04 New diagnoses of HIV in Catalonia and socioeconomic inequalities: Spatial-temporal representation with ring maps**

C. Agustí<sup>1</sup>, N. Font<sup>2</sup>, M. Julià<sup>3</sup>, A. Montoliu<sup>1</sup>, N. Vives<sup>1</sup>, F. Belvis<sup>3</sup>, J. Pericàs<sup>3</sup>, J. Casabona<sup>1</sup>, J. Benach<sup>3</sup>

<sup>1</sup>CEEISCAT-Agència de Salut Pública de Catalunya, Badalona, Spain, <sup>2</sup>Universitat de Barcelona, Barcelona, Spain, <sup>3</sup>Universitat Pompeu Fabra, Barcelona, Spain

#### **PO1/05 Hepcare Europe Manifesto**

J. Lambert<sup>1,2</sup>, W. Cullen<sup>1</sup>, G. Avramovic<sup>1,2</sup>, A. Story<sup>3</sup>, J. Surey<sup>4</sup>, J. Macías<sup>5</sup>, C. Oprea<sup>6</sup>

<sup>1</sup>University College Dublin, Phibsboro, Ireland, <sup>2</sup>Mater Misericordiae University Hospital, Dublin, Ireland, <sup>3</sup>University College London Hospital, London, United Kingdom, <sup>4</sup>University College London, London, United Kingdom, <sup>5</sup>Hospital Universitario de Valme, Seville, Spain, <sup>6</sup>Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania

#### **PO1/06 HIV prevalence and associated risk factors among Men who have Sex with Men (MSM) in Greece: A community-based approach**

S. Chanos<sup>1</sup>, A. Poullos<sup>2</sup>, M. Xanthaki<sup>3</sup>, G. Gkogidis<sup>4</sup>, G. Polkas<sup>5</sup>, S. Matis<sup>1</sup>, N. Fitsialos<sup>3</sup>, D. Antoniou<sup>3</sup>, A. Papatrechas<sup>3</sup>, P. Triantafyllou<sup>3</sup>, C. Katsioti<sup>3</sup>, P. Antonopoulos<sup>1</sup>, S. Politis<sup>1</sup>, I. Spathia<sup>1</sup>, E. Kokkali<sup>1</sup>, L. Polychronopoulou<sup>3</sup>, A. Manolopoulou<sup>5</sup>, A. Tsampouras<sup>5</sup>, V. Siderides<sup>5</sup>, V. Melita<sup>5</sup>, G. Christodoulou<sup>5</sup>

<sup>1</sup>Ath Checkpoint - Positive Voice, Athens, Greece, <sup>2</sup>Red Umbrella Athens - Positive Voice, National and Kapodistrian University of Athens, Department of Psychology, Athens, Greece, <sup>3</sup>Red Umbrella Athens - Positive Voice, Athens, Greece, <sup>4</sup>MSc student in AUEB - Positive Voice, Athens, Greece, <sup>5</sup>Thess Checkpoint - Positive Voice, Thessaloniki, Greece



### **PO1/07 Second generation HIV surveillance in people asking for HIV testing for preventive reason in Slovakia**

D. Staneková<sup>1</sup>, Z. Jaščurová<sup>1</sup>, S. Wimmerová<sup>1</sup>, M. Hábeková<sup>1</sup>, M. Mojzesová<sup>1</sup>, M. Krahulcová<sup>1</sup>

<sup>1</sup>Slovak Medical University, NRC for HIV/AIDS, Bratislava, Slovakia

### **PO1/08 Hepatitis C prevalence in Bulgaria – A stand-alone prevalence survey in the general population**

I. Sperle<sup>1</sup>, S. Nielsen<sup>2</sup>, A.J. Amato-Gauci<sup>3</sup>, M. Gassowski<sup>1</sup>, E. Kaneva<sup>4</sup>, Z. Naneva<sup>5</sup>, T. Perchemlieva<sup>5</sup>, Y. Simeonova<sup>1</sup>, E. Duffell<sup>3</sup>, R. Zimmermann<sup>1</sup>

<sup>1</sup>Robert Koch Institute, Berlin, Germany, <sup>2</sup>Independent consultant, Madrid, Spain, <sup>3</sup>European Centre for Disease Prevention and Control, Stockholm, Sweden, <sup>4</sup>Regional Health Inspectorate,, Stara Zagora, Bulgaria, <sup>5</sup>Regional Health Inspectorate, Stara Zagora, Bulgaria

### **PO1/09 An International Collaboration on Hepatitis C Elimination in HIV –Coinfection (InCHEHC) – a cohort profile**

D. van Santen<sup>1,2</sup>, R. Sacks-Davis<sup>1,3</sup>, J. Doyle<sup>1,4</sup>, K. Lacombe<sup>5</sup>, E. Cachay<sup>6</sup>, A. Pedrana<sup>1,7</sup>, J. Schinkel<sup>8,9</sup>, G. Matthews<sup>10</sup>, M. Klein<sup>11</sup>, M. van der Valk<sup>9,12</sup>, S. Saeed<sup>13</sup>, N. Chkhartishvili<sup>14</sup>, T. Tsertsvadze<sup>14</sup>, R. Altice<sup>15,16,17</sup>, A. Rauch<sup>18</sup>, L. Wittkop<sup>19,20</sup>, F. Bonnet<sup>21</sup>, M. Martinello<sup>10</sup>, J. Koopsen<sup>8,9</sup>, L. Salazar-Viscaya<sup>18</sup>, T. Applegate<sup>10</sup>, N. Martin<sup>22</sup>, P. Vickerman<sup>23</sup>, N. Scott<sup>1</sup>, M. Stoové<sup>1</sup>, M. Prins<sup>2,24</sup>, M. Hellard<sup>1</sup>

<sup>1</sup>Burnet Institute, Disease Elimination Program, Melbourne, Australia, <sup>2</sup>Public Health Service Amsterdam, Departments of Infectious Disease Research and Prevention, Amsterdam, Netherlands, <sup>3</sup>The University of Melbourne, Department of Medicine, Melbourne, Australia, <sup>4</sup>The Alfred and Monash University, Department of Infectious Diseases, Melbourne, Australia, <sup>5</sup>Universités and Inserm UMR-S1136, Infectious Diseases, AP-HP, Sorbonne, Paris, France, <sup>6</sup>University of California, Department of Medicine, San Diego, United States, <sup>7</sup>Monash University, Department of Epidemiology and Preventive Medicine, Melbourne, Australia, <sup>8</sup>Academic Medical Center, Department of Medical Microbiology, Laboratory of Clinical Virology, Amsterdam, Netherlands, <sup>9</sup>Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology, Laboratory of Clinical Virology, Amsterdam, Netherlands, <sup>10</sup>The Kirby Institute, University of New South Wales, Sydney, Australia, <sup>11</sup>McGill University Health Centre, Division of Infectious Diseases and Chronic Viral Illness Service, Montreal, Canada, <sup>12</sup>Academic Medical Centre, International Antiviral Therapy Evaluation Center and Department of Infectious Diseases, Tropical Medicine and AIDS, Amsterdam, Netherlands, <sup>13</sup>mcgill University Health Centre, Department of Epidemiology, Biostatistics and Occupational Health, Montreal, Canada, <sup>14</sup>Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia, <sup>15</sup>Yale School of Medicine, Section of Infectious Diseases, New Haven, United States, <sup>16</sup>Yale school of Medicine, Epidemiology of Microbial Diseases, New Haven, United States, <sup>17</sup>University of Malaya, Centre of Excellence in Research in AIDS, Kuala Lumpur, Malaysia, <sup>18</sup>University Hospital and University of Bern, Department of Infectious Diseases, Bern, Switzerland, <sup>19</sup>Univ. Bordeaux, ISPED, INSERM, Bordeaux Population Health Research Center, team MORPH3EUS, UMR 1219, CIC-EC 1401, Bordeaux, France, <sup>20</sup>CHU de Bordeaux, Pole de sante publique, Service d'information medicale, Bordeaux, France, <sup>21</sup>University Hospital of Bordeaux, Department of Internal Medicine, Bordeaux, France, <sup>22</sup>University of California, Division of Infectious Diseases and Global Public Health, San Diego, United States, <sup>23</sup>University of Bristol, Population Health Sciences, Bristol, United Kingdom, <sup>24</sup>Amsterdam UMC, University of Amsterdam, Department of Infectious Diseases, Amsterdam Infection and Immunity Institute (AI&II), Amsterdam, Netherlands

### **PO1/10 Gilead Sciences' Commitment to Global Elimination of Hepatitis C Virus**

N. Sajed<sup>1</sup>, K. Hutchison<sup>1</sup>, R. Haubrich<sup>1</sup>, A. Osinusi<sup>1</sup>, P. McGovern<sup>1</sup>, D. O'Farrell<sup>1</sup>, A. Hebert<sup>1</sup>, D. Medina<sup>1</sup>, K. Zuka<sup>1</sup>, P. Arora<sup>1</sup>, A. Attridge<sup>1</sup>, V. Yao<sup>1</sup>, B. Chiang<sup>1</sup>, D. Israelski<sup>1</sup>, H. Mir<sup>1</sup>, J. Ryu<sup>1</sup>, K. Vanstraelen<sup>1</sup>, T. Soyemi<sup>1</sup>, M. Mertens<sup>1</sup>, B. Kreter<sup>1</sup>

<sup>1</sup>Gilead Sciences, Inc., Foster City, United States

### **Poster Category 2: Combination Prevention**

#### **PO2/01 Having to tell: Mandatory disclosure of being HIV+ in healthcare settings in the WHO European region**

S. Beaumont<sup>1</sup>, M.D. Marek<sup>2</sup>, L. Power<sup>3</sup>, J. Hows<sup>4</sup>, E.J. Bernard<sup>3</sup>

<sup>1</sup>HIV Justice Network, Amsterdam, Netherlands, <sup>2</sup>Czech Society AIDS Help (ČSAP), Prague, Czech Republic, <sup>3</sup>HIV Justice Network, Amsterdam, Netherlands, <sup>4</sup>D.R.A.G: Development Research Advocacy Governance, Amsterdam, Netherlands

**PO2/02 Workshop: Community Designed Tool Kit to Integrate HCV Testing in HR Programs**

J. Farrell<sup>1</sup>

<sup>1</sup>Correlation-European Harm Reduction Network, Amsterdam, Netherlands

**PO2/03 Let's talk about Sex: HIV/STI prevention in medical practice. Promoting testing and diagnosis via communication trainings for doctors and medical students. A cooperation project by Deutsche AIDS-Hilfe, medical associations, the Federal Centre for Health Education (BZgA) and universities**

M. Leibnitz<sup>1</sup>, S. Taubert<sup>1</sup>

<sup>1</sup>Deutsche AIDS-Hilfe, Medicine and Consultation, Berlin, Germany

**PO2/04 Electronic Directly Observed Therapy (e-DOT) for PrEP adherence among Thai men who have sex with men: a feasibility randomized controlled trial**

T. Anand<sup>1,2</sup>, C. Nitpolprasert<sup>1,2</sup>, S.J. Kerr<sup>3,4</sup>, T. Apornpong<sup>3</sup>, J. Jantarapakde<sup>1</sup>, S. Phomthong<sup>1</sup>, P. Phoseeta<sup>1</sup>, S. Charoenying<sup>5</sup>, R. Vannakit<sup>6</sup>, P. Phanuphak<sup>1</sup>, N. Phanuphak<sup>1</sup>

<sup>1</sup>PREVENTION, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand, <sup>2</sup>Current address: Adam's Love Global Foundation for MSM and Transgender Health (ALGO), Bangkok, Thailand, <sup>3</sup>HIV-NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand, <sup>4</sup>The Kirby Institute, University of New South Wales, Sydney, Australia, <sup>5</sup>FHI 360 and USAID LINKAGES Project, Bangkok, Thailand, <sup>6</sup>Office of Public Health, U.S. Agency for International Development Regional Development Mission Asia, Bangkok, Thailand

**PO2/05 Esticom: Developing a Training Programme to help improve the skills and knowledge of Community Health Workers working with MSM on HIV, STI and Viral Hepatitis.**

B. Dwyer<sup>1</sup>, M. Kuske<sup>2</sup>

<sup>1</sup>Esticom / Terrence Higgins Trust, Health Improvement - Education and Training, London, United Kingdom, <sup>2</sup>Esticom / Deutsche AIDS Hilfe, European Project, Berlin, Germany

**PO2/06 Informal PrEP use in a cohort of MSM in Southern Spain**

M. Reiriz Rojas<sup>1</sup>, A. Berto Moran<sup>1</sup>, D. García Morcillo<sup>1</sup>, MSM in PrEP

<sup>1</sup>Adhara Sevilla Checkpoint, Sevilla, Spain

**PO2/07 Does Pre-test Counselling Increase Specific Types of Knowledge about Transmission of HIV and Viral Hepatitis B and C?**

A. Schweitzer<sup>1</sup>, M. Bogdan<sup>1</sup>, E.L. Pana<sup>1</sup>, E. Rizea<sup>1</sup>, P. Zubor<sup>1</sup>, R. Tarachiu<sup>1</sup>, C. Marinescu<sup>1</sup>, C. Turlica<sup>1</sup>

<sup>1</sup>Baylor Black Sea Foundation, Infectious diseases, Constanta, Romania

**PO2/08 ESTICOM Trainings for Community Health Worker (CHW) in Europe: first results of the Europeanwide training programme for CHW that work in the gay community**

M. Kuske<sup>1</sup>, B. Dwyer<sup>2</sup>, ESTICOM

<sup>1</sup>Deutsche AIDS-Hilfe e.V., International, Berlin, Germany, <sup>2</sup>Terrence Higgins Trust, ESTICOM, London, United Kingdom

**PO2/09 Предоставление женщинам услуг, учитывающих гендерную проблематику**

N. Minayeva<sup>1,2</sup>

<sup>1</sup>PF 'Foundation of Women Living with HIV in Kazakhstan', Темиртау, Kazakhstan, <sup>2</sup>NGO 'Center for Development and Social Assistance to the Population' My Home', Temirtau, Kazakhstan

### **Poster Category 3: Integrated Testing and Strategies**

#### **PO3/01 After the trial is over: effective implementation of the RHIVA2 research programme promoting HIV testing and diagnosis in east London primary care**

W. Leber<sup>1</sup>, J. Panovska-Griffiths<sup>2,3</sup>, F. El-Shogri<sup>4</sup>, L. Beresford<sup>4</sup>, C. Nightingale<sup>5</sup>, P. Martin<sup>2</sup>, E. Capelas Barbosa<sup>2</sup>, H. McMullen<sup>4</sup>, K. Boomla<sup>4</sup>, V. Delpech<sup>6</sup>, A. Brown<sup>6</sup>, S. Pelluri<sup>7</sup>, M. Shahmanesh<sup>2</sup>, C. Estcourt<sup>8,9</sup>, J. Hutchinson<sup>9</sup>, D. Millett<sup>7</sup>, S. Creighton<sup>7</sup>, J. Figueroa<sup>10,11</sup>, J. Anderson<sup>7</sup>, S. Morris<sup>2</sup>, N. Fulop<sup>2</sup>, C. Griffiths<sup>4</sup>

<sup>1</sup>Queen Mary University of London, Centre for Primary Care and Public Health, London, United Kingdom, <sup>2</sup>University College London, London, United Kingdom, <sup>3</sup>London School of Hygiene and Tropical Medicine, London, United Kingdom, <sup>4</sup>Queen Mary, University of London, London, United Kingdom, <sup>5</sup>St George's, University of London, London, United Kingdom, <sup>6</sup>Public Health England, London, United Kingdom, <sup>7</sup>Homerton University Hospital NHS Foundation Trust, London, United Kingdom, <sup>8</sup>Glasgow Caledonian University, London, United Kingdom, <sup>9</sup>Barts Health NHS Trust, London, United Kingdom, <sup>10</sup>NHS England, London, United Kingdom, <sup>11</sup>NHS City and Hackney, London, United Kingdom

#### **PO3/02 The Greek "Checkpoint" success story in safeguarding public health: First community-based prevention and testing centre in Greece diagnoses 30% of the 2017 national HIV cases**

S. Chanos<sup>1</sup>, G. Polkas<sup>2</sup>, G. Gkogidis<sup>3</sup>, S. Matis<sup>1</sup>, P. Antonopoulos<sup>1</sup>, S. Politis<sup>1</sup>, I. Spathia<sup>1</sup>, E. Kokkali<sup>1</sup>, N. Fitsialos<sup>4</sup>, L. Polychronopoulou<sup>4</sup>, D. Antoniou<sup>4</sup>, A. Manolopoulou<sup>2</sup>, A. Tsampouras<sup>2</sup>, V. Siderides<sup>2</sup>, V. Melita<sup>2</sup>, G. Christodoulou<sup>2</sup>

<sup>1</sup>Ath Checkpoint - Positive Voice, Athens, Greece, <sup>2</sup>Thess Checkpoint – Positive Voice, Thessaloniki, Greece, <sup>3</sup>MSc student in AUEB - Positive Voice, Athens, Greece, <sup>4</sup>Red Umbrella Athens - Positive Voice, Athens, Greece

#### **PO3/03 Implementation of HIV infection hospital-based active case finding in Sardinia, Italy: Results from the shot project**

M.S. Mameli<sup>1</sup>, P. Bagella<sup>1</sup>, F. Melis<sup>1</sup>, C. Fozza<sup>2</sup>, A. Murtas<sup>2</sup>, M.A. Montesu<sup>3</sup>, G. Deligia<sup>3</sup>, A.G. Fois<sup>4</sup>, S. Negri<sup>4</sup>, F. Filigheddu<sup>5</sup>, N. Manzoni<sup>6</sup>, S. Babudieri<sup>1</sup>, G. Madeddu<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, University of Sassari, Department of Medical, Surgical and Experimental Sciences, Sassari, Italy, <sup>2</sup>Unit of Hematology, University of Sassari, Department of Medical, Surgical and Experimental Sciences, Sassari, Italy, <sup>3</sup>Unit of Dermatology, University of Sassari, Department of Medical, Surgical and Experimental Sciences, Sassari, Italy, <sup>4</sup>Unit of Respiratory Diseases, University of Sassari, Department of Medical, Surgical and Experimental Sciences, Sassari, Italy, <sup>5</sup>Unit of Internal Medicine, University of Sassari, Department of Medical, Surgical and Experimental Sciences, Sassari, Italy, <sup>6</sup>Unit of Internal Medicine, University of Sassari, University Hospital of Sassari, Sassari, Italy

#### **PO3/04 A qualitative study of acceptability of rapid screening for HIV, Hepatitis B, and Hepatitis C among migrants in France (STRADA study)**

M. Duracinsky<sup>1</sup>, F. Thonon<sup>1</sup>, S. Bun<sup>1</sup>, I. Ben Nasr<sup>1</sup>, A. Fofana Dara<sup>1</sup>, S. Lakhdari<sup>1</sup>, F. Lert<sup>2</sup>, D. Zucman<sup>3</sup>, S. Dimi<sup>3</sup>, O. Chassany<sup>1,4</sup>

<sup>1</sup>EA7334REMES, Paris, France, <sup>2</sup>ANRS, Paris, France, <sup>3</sup>Hopital Foch, hépatologie, Suresne, France, <sup>4</sup>Université Paris Diderot, Paris, France

#### **PO3/05 Low access to HIV and HCV testing among People Who Inject Drugs (PWID) in Poland. Cross-sectional multicenter study 2017**

K. Zakrzewska<sup>1</sup>, K. Szmulik<sup>1</sup>, M. Rosińska<sup>1</sup>

<sup>1</sup>National Institute of Public Health – National Institute of Hygiene, Department of Epidemiology of Infection Disease and Surveillance, Warsaw, Poland

### **PO3/06 How can we test for HIV, HCV and syphilis - experience from Polish NGO**

M. Ankiersztejn-Bartczak<sup>1</sup>

<sup>1</sup>Foundation for Social Education, Warsaw, Poland

### **PO3/07 Evaluation of a new strategy for screening migrants: the STRADA study design**

M. Duracinsky<sup>1</sup>, F. Thonon<sup>1</sup>, F. Lert<sup>2</sup>, O. Rousset<sup>1</sup>, D. Zucman<sup>3</sup>, P. Sogni<sup>4</sup>, T. Leluong<sup>5</sup>, F. Roudot-Thoraval<sup>6</sup>, I. Normand<sup>5</sup>, O. Chassany<sup>1,7</sup>

<sup>1</sup>EA7334REMES, Paris, France, <sup>2</sup>ANRS, Paris, France, <sup>3</sup>Hopital Foch, hépatologie, Suresne, France, <sup>4</sup>Hopital Cochin, Paris, France, <sup>5</sup>OFII, Paris, France, <sup>6</sup>Hopital Henri Mondor, Hépatologie, Créteil, France, <sup>7</sup>Université Paris Diderot, Paris, France

### **PO3/08 S.A.M: the new homesampling service in Germany**

M. Tappe<sup>1</sup>, A. Schafberger<sup>2</sup>, G. Davies<sup>3</sup>

<sup>1</sup>Deutsche AIDS-Hilfe, Berlin, Germany, <sup>2</sup>Deutsche AIDS-HilfeAIDS-Hilfe, Berlin, Germany, <sup>3</sup>Disrupt Care Ltd, London, United Kingdom

## **Poster Category 4: Linkage to Care**

### **PO4/01 HIV self-sampling and self-testing in Europe: a systematic review**

S. Croxford<sup>1</sup>, L. Tivoschi<sup>2,3</sup>, A. Sullivan<sup>4</sup>, L. Combs<sup>5</sup>, D. Raben<sup>5</sup>, V. Delpech<sup>1</sup>, S. Finne Jakobson<sup>5</sup>, A. Amato-Gauci<sup>2</sup>, S. Desai<sup>1</sup>

<sup>1</sup>Public Health England, London, United Kingdom, <sup>2</sup>European Centre for Disease Prevention and Control, Solna, Sweden, <sup>3</sup>University of Pisa, Pisa, Italy, <sup>4</sup>Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom, <sup>5</sup>Centre of Excellence for Health, Immunity and Infections, Copenhagen, Denmark

### **PO4/02 HepCare Europe – HCV screening and linkage to care in key populations from the Romanian clinical site**

I. Ianache<sup>1</sup>, S. Lazar<sup>1,2</sup>, I. Popa<sup>1</sup>, I. Petre<sup>3</sup>, A. Luca<sup>1</sup>, A. Dumitriu<sup>4</sup>, A. Kosa<sup>1</sup>, S. Florescu<sup>1,2</sup>, C. Oprea<sup>1,2</sup>

<sup>1</sup>Victor Babes Hospital, Bucharest, Romania, <sup>2</sup>Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, <sup>3</sup>Carusel, Bucharest, Romania, <sup>4</sup>ARAS – Romanian Association Against AIDS, Bucharest, Romania

### **PO4/03 Adherence to Antiretroviral Treatment among the People Living with HIV in Armenia**

T. Balayan<sup>1</sup>

<sup>1</sup>American University of Armenia, Public Health, Yerevan, Armenia

### **PO4/04 Case Management Program for HIV among MSM in Kyiv, Ukraine and linkage to care, at the context the implementation of UNAIDS 90-90-90 Strategy**

A. Chernyshev<sup>1</sup>, Y. Yanishin<sup>2</sup>, T. Honcharov<sup>2</sup>, R. Marchenko<sup>3</sup>

<sup>1</sup>ALLIANCE.GLOBAL, Public Organization, Advocacy & External Communication Department, Kyiv, Ukraine, <sup>2</sup>ALLIANCE.GLOBAL, Public Organization, Kyiv, Ukraine, <sup>3</sup>ALLIANCE.GLOBAL, Public Organization, Program Department, Kyiv, Ukraine

**PO4/05 Micro-elimination as a strategy for improved access to testing and linkage to care for viral hepatitis C amongst high-risk groups in Europe**

S.R. Stumo<sup>1</sup>, M. Maticic<sup>2,3</sup>, M. Harris<sup>4</sup>, A.M. Metwally<sup>5,6</sup>, M. Jauffret-Roustide<sup>7</sup>, G. Hendrickx<sup>8</sup>, T. Reic<sup>9</sup>, J.V. Lazarus<sup>1,10</sup>, on behalf of the Hep-CORE Study Group

<sup>1</sup>Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain, <sup>2</sup>University Medical Centre Ljubljana, Clinic for Infectious Diseases and Febrile Illnesses, Ljubljana, Slovenia, <sup>3</sup>University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, <sup>4</sup>London School of Hygiene and Tropical Medicine, Department of Social and Environmental Health Research, London, United Kingdom, <sup>5</sup>National Research Centre, Giza, Egypt, <sup>6</sup>Association of Liver Patient Care, Dakhlyia, Egypt, <sup>7</sup>Inserm U988, CNRS 8211/EHESS/Paris Descartes University, Cermes3, Paris, France, <sup>8</sup>University of Antwerp, Viral Hepatitis Prevention Board, Antwerp, Belgium, <sup>9</sup>European Liver Patients' Association, Brussels, Belgium, <sup>10</sup>CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

**PO4/06 „Be my buddy“ How peer educators can support linkage to care and fight stigma**

T. Vogler<sup>1</sup>

<sup>1</sup>Deutsche AIDS-Hilfe e.V., Berlin, Germany